The recent finding of the critical role of IL23 and IL17 in the pathogenesis of IBD and other immune-mediated diseases has led to the development of new therapeutic approaches targeting these cytokines and corresponding receptors (56, 80, 81). This evidence concerns the gene IL23A and inflammatory bowel disease.